EMCURE PHARMACEUTICALS L EMCURE NIFTY_SMALLNSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India

https://www.emcure.com

Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the development and commercialization of Poviztra, a semaglutide injection for weight loss. Emcure Pharmaceuticals Limited was incorporated in 1981 and is based in Pune, India.

Market & Price

Market Cap

₹32,166.26 Cr

Current Price

₹1,696.00

High / Low (52W)

₹1,793.20 / ₹1,240.53

Beta

Valuation

Stock P/E

34.73

Industry PE

37.60

Forward P/E

22.77

PEG Ratio

Book Value

₹261.12

Price to Book

6.49

P/S

3.49

EV/EBITDA

18.76

Dividend Yield

0.18%

Profitability & Returns

ROCE

25.10%

ROE

19.57%

ROA

9.62%

Profit Margin

10.04%

Op Margin

15.35%

EPS (Latest Qtr)

₹12.84

EPS (TTM)

₹48.84

Balance Sheet & Liquidity

Debt/Equity

0.31

Quick Ratio

0.71

Current Ratio

1.43

Debt

₹1,521.24 Cr

Total Assets

₹9,612.48 Cr

Current Assets

₹5,612.10 Cr

Working Capital

₹1,699.86 Cr

Ownership

Promoter Holding

81.71%

Chg in Prom Hold

FII / Inst Holding

5.36%

Chg in FII Hold

Financial Snapshot

Enterprise Value

₹33,550.79 Cr

Total Revenue (TTM)

₹9,203.54 Cr

EBITDA

₹1,788.61 Cr

Free Cash Flow

₹311.29 Cr

Operating Cash Flow

₹943.55 Cr

Shares Outstanding

₹18.97 Cr

Gross Margin

60.27%

Payout Ratio

6.15%

Growth (CAGR)

Revenue 5Y

15.77%

Profit 5Y

20.22%

Revenue (YoY)

16.70%

Earnings (YoY)

28.80%

PROS

Healthy ROCE of 25.1%.
Compounding revenue at 15.8% over 5 years.
Profit CAGR of 20.2% over 5 years.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	EMCURE EMCURE PHARMACEUTICALS L NIFTY_SMALLNSEPHARMA	1,696.00	34.73	₹32,166.26 Cr	0.18%	25.10%	19.57%	15.77%	20.22%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,799.20	37.59	₹4.32 L Cr	0.92%	17.94%	14.72%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	6,667.00	68.97	₹1.77 L Cr	0.45%	18.96%	16.19%	11.27%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,410.80	68.96	₹1.49 L Cr	0.86%	9.06%	16.98%	13.27%	20.21%
5	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,401.00	29.16	₹1.13 L Cr	0.93%	14.88%	11.74%	7.23%	11.45%
6	DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA	1,303.50	25.90	₹1.09 L Cr	0.61%	14.00%	11.83%	10.96%	-2.35%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,077.70	21.51	₹1.08 L Cr	0.09%	19.24%	18.32%	16.55%	36.99%
8	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,267.70	19.49	₹1.04 L Cr	0.53%	28.42%	26.91%	19.10%	131.46%
9	MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA	2,375.60	51.29	₹98,090.71 Cr	0.08%	13.78%	12.45%	17.73%	14.28%

Quarterly Results

Figures in INR.

Metric	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	2,116.24 Cr	2,100.54 Cr	2,269.82 Cr	2,363.48 Cr	2,469.70 Cr
Cost of Revenue	-	892.11 Cr	802.01 Cr	889.53 Cr	962.43 Cr	1,003.09 Cr
Gross Profit	-	1,224.13 Cr	1,298.52 Cr	1,380.29 Cr	1,401.05 Cr	1,466.61 Cr
Operating Expenses	-	931.05 Cr	994.09 Cr	1,045.81 Cr	1,045.61 Cr	1,087.41 Cr
Operating Income	-	293.09 Cr	304.43 Cr	334.48 Cr	355.44 Cr	379.21 Cr
EBITDA	-	396.48 Cr	416.97 Cr	478.60 Cr	456.45 Cr	493.84 Cr
Interest Expense	-	39.02 Cr	26.75 Cr	32.54 Cr	37.98 Cr	46.40 Cr
Pretax Income	-	260.61 Cr	290.76 Cr	341.42 Cr	313.79 Cr	341.18 Cr
Tax Provision	-	63.38 Cr	75.97 Cr	90.05 Cr	82.42 Cr	97.44 Cr
Net Income	-	188.96 Cr	206.95 Cr	243.46 Cr	230.54 Cr	243.40 Cr
Diluted EPS	-	9.97	10.92	12.85	12.16	12.84

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	-	5,931.08 Cr	6,581.99 Cr	7,896.00 Cr	9,203.54 Cr
Cost of Revenue	-	2,408.09 Cr	2,609.58 Cr	3,146.60 Cr	3,657.06 Cr
Gross Profit	-	3,522.98 Cr	3,972.41 Cr	4,749.39 Cr	5,546.48 Cr
Operating Expenses	-	2,582.36 Cr	3,055.10 Cr	3,664.67 Cr	4,172.92 Cr
Operating Income	-	940.63 Cr	917.32 Cr	1,084.73 Cr	1,373.56 Cr
EBITDA	-	1,170.25 Cr	1,240.33 Cr	1,531.31 Cr	1,845.86 Cr
Interest Expense	-	162.91 Cr	200.69 Cr	175.78 Cr	143.67 Cr
Pretax Income	-	747.22 Cr	727.23 Cr	971.35 Cr	1,287.14 Cr
Tax Provision	-	185.37 Cr	199.65 Cr	263.88 Cr	345.87 Cr
Net Income	-	532.02 Cr	498.18 Cr	681.33 Cr	924.36 Cr
Diluted EPS	-	29.43	27.57	36.43	48.77

Compounded Sales Growth

5 Years:	15.77%
1 Year:	16.70%

Compounded Profit Growth

5 Years:	20.22%
1 Year:	28.80%

Stock Price Performance

1 Year:	+25.71%
6 Months:	+24.53%
3 Months:	+18.14%
1 Month:	-1.96%

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Assets	-	6,672.53 Cr	7,806.16 Cr	8,232.72 Cr	9,612.48 Cr
Current Assets	-	3,835.91 Cr	4,259.91 Cr	4,555.86 Cr	5,612.10 Cr
Cash & Equivalents	-	56.37 Cr	108.96 Cr	121.82 Cr	136.66 Cr
Inventory	-	1,383.03 Cr	1,525.10 Cr	1,931.81 Cr	2,397.87 Cr
Receivables	-	1,648.30 Cr	1,858.81 Cr	2,002.24 Cr	2,562.66 Cr
Total Liabilities	-	4,022.87 Cr	4,684.40 Cr	3,591.17 Cr	4,635.81 Cr
Current Liabilities	-	3,019.19 Cr	3,210.47 Cr	2,668.27 Cr	3,912.24 Cr
Long Term Debt	-	744.13 Cr	766.60 Cr	189.94 Cr	252.21 Cr
Total Debt	-	2,334.30 Cr	2,334.97 Cr	1,022.75 Cr	1,521.24 Cr
Total Equity	-	2,501.13 Cr	2,952.28 Cr	4,446.19 Cr	4,950.03 Cr
Shares Outstanding	-	18.91 Cr	18.91 Cr	18.95 Cr	18.96 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow	-	746.85 Cr	1,097.24 Cr	851.71 Cr	943.54 Cr
Investing Cash Flow	-	-467.69 Cr	-712.51 Cr	-94.00 Cr	-1,193.06 Cr
Financing Cash Flow	-	-145.40 Cr	-164.21 Cr	-813.96 Cr	343.43 Cr
Capital Expenditure	-	-403.36 Cr	-307.13 Cr	-406.93 Cr	-547.69 Cr
Free Cash Flow	-	343.49 Cr	790.11 Cr	444.78 Cr	395.86 Cr
Net Change in Cash	-	133.77 Cr	220.52 Cr	-56.25 Cr	93.92 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Gross Margin %	-	59.4%	60.4%	60.1%	60.3%
Operating Margin %	-	15.9%	13.9%	13.7%	14.9%
Net Margin %	-	9.0%	7.6%	8.6%	10.0%
ROE %	-	21.3%	16.9%	15.3%	18.7%
ROCE %	-	25.7%	20.0%	19.5%	24.1%

Shareholding Pattern

Insiders

81.71%

Institutions

5.36%

Public Float

29.29%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for EMCURE

No recent headlines available.

EMCURE · Healthcare